寡转移性膀胱癌的定义与诊断:欧洲泌尿外科学会、欧洲放射肿瘤学会和欧洲肿瘤内科学会泌尿生殖分会认可的德尔菲共识研究
本研究采用改良德尔菲法,由29名欧洲专家组成的共识小组制定寡转移性膀胱癌(OMBC)的定义、分类和分期推荐。定义限于新发OMBC,进一步分为同时性寡转移、寡复发和寡进展;最多三个可切除或适合立体定向治疗的转移部位;盆腔淋巴结是唯一不纳入OMBC定义的「器官」。
要点
- OMBC定义为最多三个可切除或适合立体定向治疗的转移部位。
- OMBC分类包括同时性寡转移、寡复发和寡进展。
- 盆腔淋巴结是唯一不纳入OMBC定义的「器官」。
核心结论
- 已制定关于OMBC定义和分期的共识声明,将有助于标准化未来试验的纳入标准,促进对未达成共识方面的研究,并有望推动OMBC最佳管理指南的制定。
研究设计与样本
- 由欧洲泌尿外科学会(EAU)、欧洲放射肿瘤学会(ESTRO)和欧洲肿瘤内科学会(ESMO)领导,包括来自所有其他相关欧洲学会成员的29名专家组成的欧洲共识小组。
- 采用改良德尔菲法,通过系统评价构建共识问题,从两次连续调查中提取共识声明,在两次共识会议期间制定声明,一致同意水平≥75%视为达成共识。
主要发现
- 第一次调查包括14个问题,第二次调查包括12个问题。
- 由于证据严重缺乏(为主要局限性),定义仅限于新发OMBC的背景下,进一步分类为同时性OMD、寡复发和寡进展。
- 提出最多三个转移部位(所有可切除或适合立体定向治疗)作为OMBC的定义。
- 盆腔淋巴结是唯一不纳入OMBC定义的「器官」。
- 对于分期,未就18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的作用达成共识。
关键数值与推荐
- OMBC定义:最多三个转移部位,所有可切除或适合立体定向治疗。
- OMBC分类:同时性寡转移、寡复发、寡进展。
- 盆腔淋巴结是唯一不纳入OMBC定义的「器官」。
- 对全身治疗的良好反应被提出作为选择患者进行转移导向治疗的 criterion。
- 未就18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在分期中的作用达成共识。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据严重缺乏是主要局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In contrast to other cancers, the concept of oligometastatic disease (OMD) has not been investigated in bladder cancer (BC). OBJECTIVE: To develop an acceptable definition, classification, and staging recommendations for oligometastatic BC (OMBC) spanning the issues of patient selection and the roles of systemic therapy and ablative local therapy. DESIGN, SETTING, AND PARTICIPANTS: A European consensus group of 29 experts, led by the European Association of Urology (EAU), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Medical Oncology (ESMO), and including members from all other relevant European societies, was established. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A modified Delphi method was used. A systematic review was used to build consensus questions. Consensus statements were extracted from two consecutive surveys. The statements were formulated during two consensus meetings. Agreement levels were measured to determine if consensus was achieved (≥75% agreement). RESULTS AND LIMITATIONS: The first survey included 14 questions and the second survey had 12. Owing to a considerable lack of evidence, which was the major limitation, definition was limited in the context of de novo OMBC, which was further classified as synchronous OMD, oligorecurrence, and oligoprogression. A maximum of three metastatic sites, all resectable or amenable to stereotactic therapy, was proposed as the definition of OMBC. Pelvic lymph nodes represented the only "organ" not included in the definition of OMBC. For staging, no consensus on the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography was reached. A favourable response to systemic treatment was proposed as the criterion for selection of patients for metastasis-directed therapy. CONCLUSIONS: A consensus statement on the definition and staging of OMBC has been formulated. This statement will help to standardise inclusion criteria in future trials, potentiate research on aspects of OMBC for which consensus was not achieved, and hopefully will lead to the development of guidelines on optimal management of OMBC. PATIENT SUMMARY: As an intermediate state between localised cancer and disease with extensive metastasis, oligometastatic bladder cancer (OMBC) might benefit from a combination of systemic treatment and local therapy. We report the first consensus statements on OMBC drawn up by an international expert group. These statements can provide a basis for standardisation of future research, which will lead to high-quality evidence in the field.
引用
- Bamias A, Stenzl A, Brown SL, et al. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023. PMID: 37217391. doi:10.1016/j.eururo.2023.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。